Table 3.
ALK inhibitors used in the first-line setting.
| TKI | Brigatinib | Crizotinib | Alectinib | Ceritinib |
|---|---|---|---|---|
| Trial | ALTA-1L (85) | ALEX (86, 87) | ALEX (86, 87) | ASCEND-4 (88) |
| Comparators | Crizotinib | Alectinib | Crizotinib | Platinum-based doublet |
| N | 137 | 151 | 152 | 189 |
| Median PFS (months) | NR | 10.4 | 34.8 | 16.6 |
| PFS HR (95% CI) | – | – | 0.5 (0.36–0.7)** | 0.55 (0.42–0.73)* |
| ORR (%) | 71 | 75.5 | 82.9 | 72.5 |
| Median PFS MC+ (months) | NR | 7.4 | NR > 27 | 10.7 |
| Intra cranial ORR (%) | 78 | 50 | 81 | 72.7 |
ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; N, number of patients; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ORR, objective response rate; MC+, patients with central nervous system metastases; NR, not reached.
*
vs. chemotherapy.
**
vs. crizotinib.